Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction

JACC: Heart Failure

Volumn 3, Issue 6, 2015, Pages 467-474

  Al Naamani, Nadine ^a   Preston, Ioana R ^a   Paulus, Jessica K ^b   Hill, Nicholas S ^a   Roberts, Kari E ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

Heart failure with preserved ejection fraction; Pulmonary heart disease; Survival; Vasodilation

Indexed keywords

NITRIC OXIDE;

ADULT; AGED; ARTICLE; BLOOD VESSEL CAPACITANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIASTOLIC PRESSURE GRADIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HEMODYNAMICS; HEMODYNAMIC PARAMETERS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY ARTERIAL CAPACITANCE; PULMONARY ARTERY; PULMONARY HYPERTENSION; PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE; SURVIVAL RATE; TRANSPULMONARY GRADIENT; COMPLICATION; HEART FAILURE; HYPERTENSION, PULMONARY; LUNG WEDGE PRESSURE; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC;

AGED; CARDIAC CATHETERIZATION; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY ARTERY; PULMONARY WEDGE PRESSURE; ROC CURVE;

EID: 84930837572     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.01.013     Document Type: Article

References (33)

1. Hill N.S., Preston I., Roberts K. Defining the phenotypes for pulmonary hypertension associated with diastolic heart failure. Circ Heart Fail 2011, 4:238-240.
2. Hogg K., Swedberg K., McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. JAm Coll Cardiol 2004, 43:317-327.
3. Damy T., Goode K.M., Kallvikbacka-Bennett A., et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J 2010, 31:2280-2290.
4. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537.
5. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. JAm Coll Cardiol 2009, 53:1573-1619.
6. Thenappan T., Shah S.J., Gomberg-Maitland M., et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011, 4:257-265.
7. Hansdottir S., Groskreutz D.J., Gehlbach B.K. WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension. Chest 2013, 144:638-650.
8. Vachiery J.L., Adir Y., Barbera J.A., et al. Pulmonary hypertension due to left heart diseases. JAm Coll Cardiol 2013, 62:D100-D108.
9. Cappola T.P., Felker G.M., Kao W.H., Hare J.M., Baughman K.L., Kasper E.K. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002, 105:1663-1668.
10. Ghio S., Gavazzi A., Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. JAm Coll Cardiol 2001, 37:183-188.
11. Dupont M., Mullens W., Skouri H.N., et al. Prognostic role of pulmonary arterial capacitance in advanced heart failure. Circ Heart Fail 2012, 5:778-785.
12. Pellegrini P., Rossi A., Pasotti M., et al. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest 2014, 145:1064-1070.
13. Costard-Jackle A., Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. JAm Coll Cardiol 1992, 19:48-54.
14. Schwartzenberg S., Redfield M.M., From A.M., Sorajja P., Nishimura R.A., Borlaug B.A. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. JAm Coll Cardiol 2012, 59:442-451.
15. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355:251-259.
16. Preston I.R., Klinger J.R., Houtches J., Nelson D., Farber H.W., Hill N.S. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med 2005, 99:1501-1510.
17. Preston I.R., Sagliani K.D., Roberts K.E., et al. Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension. Pulm Circ 2013, 3:68-73.
18. Sitbon O., Brenot F., Denjean A., et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995, 151:384-389.
19. Rich S., Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. JAm Coll Cardiol 1991, 18:1323-1327.
20. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111:3105-3111.
21. Agarwal R., Shah S.J., Foreman A.J., et al. Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. JHeart Lung Transplant 2012, 31:467-477.
22. Lam C.S., Roger V.L., Rodeheffer R.J., Borlaug B.A., Enders F.T., Redfield M.M. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. JAm Coll Cardiol 2009, 53:1119-1126.
23. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlatedreceiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
24. Lankhaar J.W., Westerhof N., Faes T.J., et al. Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol 2006, 291:H1731-H1737.
25. Westerhof N., Lankhaar J.W., Westerhof B.E. The arterial Windkessel. Med Biol Eng Comput 2009, 47:131-141.
26. Lankhaar J.W., Westerhof N., Faes T.J., et al. Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J 2008, 29:1688-1695.
27. Tedford R.J., Hassoun P.M., Mathai S.C., et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 2012, 125:289-297.
28. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
29. Roger V.L., Weston S.A., Redfield M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.
30. Miller W.L., Grill D.E., Borlaug B.A. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JAm Coll Cardiol HF 2013, 1:290-299.
31. Domanski M.J., Mitchell G.F., Norman J.E., Exner D.V., Pitt B., Pfeffer M.A. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. JAm Coll Cardiol 1999, 33:951-958.
32. Scott D., Tan Y., Shandas R., Stenmark K.R., Tan W. High pulsatility flow stimulates smooth muscle cell hypertrophy and contractile protein expression. Am J Physiol Lung Cell Mol Physiol 2013, 304:L70-L81.
33. Douwes J.M., van Loon R.L., Hoendermis E.S., et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J 2011, 32:3137-3146.